Company intelligence / Profile preview

Vernagen

Atlanta, Georgia, United States

Ownership: Private
Development stage: Other

Overview

Vernagen is developing mRNA-based vaccines and therapeutic biologics; its pipeline of prophylactic mRNA vaccines for multiple infectious diseases is currently in discovery and preclinical stages, with no clinical trial results reported yet.[1][6]

Therapeutic areas: ImmunologyRare DiseasesInfectious Diseases
Modalities: mRNA-based drugsVaccineBiologic
Industry: Biotech

Drug pipeline

4 assets

VER-027

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

ST Pharm (mRNA Center collaboration in global R&D; Vernagen listed as partner in innovative RNA therapeutics and mRNA cancer vaccines/therapeutics initiative)[4]

Beyond the preview

Go deeper on Vernagen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vernagen.

Explore the full profile